O'Dea Offers Insight Into the Integration of Trastuzumab Deruxtecan in HER2+ Breast Cancer

Dr. O’Dea discusses the efficacy and safety of trastuzumab deruxtecan in patients with HER2-positive breast cancer, treatment sequencing recommendations, and future research directions for antibody-drug conjugates in the field.

Welcome to OncLive On AirTM! I’m your host today, Jessica Hergert.

OncLive On AirTM is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Daiichi Sankyo, Inc., we had the pleasure of speaking with Anne P. O’Dea, MD, an assistant professor of oncology at Kansas University Medical Center, to discuss key efficacy data from the DESTINY-Breast01 trial and the integration of fam-trastuzumab deruxtecan-nxki (Enhertu) into the HER2-positive breast cancer armamentarium.

In our exclusive interview, O’Dea discussed the efficacy and safety of trastuzumab deruxtecan in patients with HER2-positive breast cancer, treatment sequencing recommendations, and future research directions for antibody-drug conjugates in the field.

Dr. O'Dea has done speaking and consulting for Daiichi Sankyo, Inc.